Lipid mediators in immune dysfunction after severe inflammation

Lipid mediators in immune dysfunction after severe inflammation

Highlights • Aberrant LM levels contribute to immune dysfunction in CI. • Aberrance reflects dysregulation of inflammatory resolution pathways or their failure. • Targeted manipulation of LMs restores immune competence and outcomes in animal models. • Stratified resolution-based immunomodulatory str...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Trends in immunology 2014-01, Vol.35 (1), p.12-21
Hauptverfasser: Fullerton, James N, O’Brien, Alastair J, Gilroy, Derek W
Format: Artikel
Sprache:eng
Schlagworte:
Allergy and Immunology
Animals
Antibiotics
Apoptosis
Clinical outcomes
Critical Illness
cyclooxygenase
eicosanoids
Humans
Immune system
immunosuppression
Inflammation - etiology
Inflammation - immunology
Inflammation - metabolism
Inflammation - therapy
Inflammation Mediators - metabolism
Lipid Metabolism - immunology
Lipids
Mortality
Nonsteroidal anti-inflammatory drugs
Nosocomial infections
prostaglandins
resolution of inflammation
Review
Rodents
Sepsis
Signal Transduction
Viral infections
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Highlights • Aberrant LM levels contribute to immune dysfunction in CI. • Aberrance reflects dysregulation of inflammatory resolution pathways or their failure. • Targeted manipulation of LMs restores immune competence and outcomes in animal models. • Stratified resolution-based immunomodulatory strategies hold therapeutic potential.
ISSN:1471-4906
1471-4981
DOI:10.1016/j.it.2013.10.008